Pharming NV and Santarus Inc. have submitted a new BLA for Ruconest (recombinant human C1 esterase inhibitor) to FDA for treating acute hereditary angioedema attacks, but the delay from the in
IN VITRO DIAGNOSTICS Mergers & Acquisitions Abingdon Health Ltd. Molecular Vision Ltd. Abingdon Health Ltd. has purchased a 50.1% equity stake in fellow private diagnostics firm Molecular Vision
Pharming NV and Santarus Inc. have submitted a new BLA for Ruconest (recombinant human C1 esterase inhibitor) to FDA for treating acute hereditary angioedema attacks, but the delay from the in